IBDEI39Y ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,55029,0)
 ;;=D47.4^^256^2775^173
 ;;^UTILITY(U,$J,358.3,55029,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55029,1,3,0)
 ;;=3^Osteomyelofibrosis
 ;;^UTILITY(U,$J,358.3,55029,1,4,0)
 ;;=4^D47.4
 ;;^UTILITY(U,$J,358.3,55029,2)
 ;;=^5002259
 ;;^UTILITY(U,$J,358.3,55030,0)
 ;;=D59.1^^256^2775^27
 ;;^UTILITY(U,$J,358.3,55030,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55030,1,3,0)
 ;;=3^Autoimmune Hemolytic Anemia,Other
 ;;^UTILITY(U,$J,358.3,55030,1,4,0)
 ;;=4^D59.1
 ;;^UTILITY(U,$J,358.3,55030,2)
 ;;=^5002324
 ;;^UTILITY(U,$J,358.3,55031,0)
 ;;=D51.3^^256^2775^187
 ;;^UTILITY(U,$J,358.3,55031,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55031,1,3,0)
 ;;=3^Vitamin B12 Deficiency Anemia,Other
 ;;^UTILITY(U,$J,358.3,55031,1,4,0)
 ;;=4^D51.3
 ;;^UTILITY(U,$J,358.3,55031,2)
 ;;=^5002287
 ;;^UTILITY(U,$J,358.3,55032,0)
 ;;=D77.^^256^2775^55
 ;;^UTILITY(U,$J,358.3,55032,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55032,1,3,0)
 ;;=3^Disorder of Blood/Blood-Forming Organs in Diseases Classified Elsewhere,Other
 ;;^UTILITY(U,$J,358.3,55032,1,4,0)
 ;;=4^D77.
 ;;^UTILITY(U,$J,358.3,55032,2)
 ;;=^5002396
 ;;^UTILITY(U,$J,358.3,55033,0)
 ;;=D58.2^^256^2775^81
 ;;^UTILITY(U,$J,358.3,55033,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55033,1,3,0)
 ;;=3^Hemoglobinopathies,Other
 ;;^UTILITY(U,$J,358.3,55033,1,4,0)
 ;;=4^D58.2
 ;;^UTILITY(U,$J,358.3,55033,2)
 ;;=^87629
 ;;^UTILITY(U,$J,358.3,55034,0)
 ;;=C88.8^^256^2775^101
 ;;^UTILITY(U,$J,358.3,55034,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55034,1,3,0)
 ;;=3^Malig Immunoproliferative Diseases,Other
 ;;^UTILITY(U,$J,358.3,55034,1,4,0)
 ;;=4^C88.8
 ;;^UTILITY(U,$J,358.3,55034,2)
 ;;=^5001750
 ;;^UTILITY(U,$J,358.3,55035,0)
 ;;=D70.8^^256^2775^170
 ;;^UTILITY(U,$J,358.3,55035,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55035,1,3,0)
 ;;=3^Neutropenia,Other
 ;;^UTILITY(U,$J,358.3,55035,1,4,0)
 ;;=4^D70.8
 ;;^UTILITY(U,$J,358.3,55035,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,55036,0)
 ;;=D59.4^^256^2775^171
 ;;^UTILITY(U,$J,358.3,55036,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55036,1,3,0)
 ;;=3^Nonautoimmune Hemolytic Anemias,Other
 ;;^UTILITY(U,$J,358.3,55036,1,4,0)
 ;;=4^D59.4
 ;;^UTILITY(U,$J,358.3,55036,2)
 ;;=^5002326
 ;;^UTILITY(U,$J,358.3,55037,0)
 ;;=D69.59^^256^2775^177
 ;;^UTILITY(U,$J,358.3,55037,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55037,1,3,0)
 ;;=3^Secondary Thrombocytopenia,Other
 ;;^UTILITY(U,$J,358.3,55037,1,4,0)
 ;;=4^D69.59
 ;;^UTILITY(U,$J,358.3,55037,2)
 ;;=^5002369
 ;;^UTILITY(U,$J,358.3,55038,0)
 ;;=C22.7^^256^2775^44
 ;;^UTILITY(U,$J,358.3,55038,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55038,1,3,0)
 ;;=3^Carcinomas of Liver,Other Spec
 ;;^UTILITY(U,$J,358.3,55038,1,4,0)
 ;;=4^C22.7
 ;;^UTILITY(U,$J,358.3,55038,2)
 ;;=^5000938
 ;;^UTILITY(U,$J,358.3,55039,0)
 ;;=D75.89^^256^2775^54
 ;;^UTILITY(U,$J,358.3,55039,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55039,1,3,0)
 ;;=3^Diseases of Blood/Blood-Forming Organs,Other Spec
 ;;^UTILITY(U,$J,358.3,55039,1,4,0)
 ;;=4^D75.89
 ;;^UTILITY(U,$J,358.3,55039,2)
 ;;=^5002392
 ;;^UTILITY(U,$J,358.3,55040,0)
 ;;=D47.Z9^^256^2775^169
 ;;^UTILITY(U,$J,358.3,55040,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55040,1,3,0)
 ;;=3^Neop Lymphoid,Hematopoietic & Related Tissue,Uncertain Behavior,Other
 ;;^UTILITY(U,$J,358.3,55040,1,4,0)
 ;;=4^D47.Z9
 ;;^UTILITY(U,$J,358.3,55040,2)
 ;;=^5002262
 ;;^UTILITY(U,$J,358.3,55041,0)
 ;;=D05.82^^256^2775^32
 ;;^UTILITY(U,$J,358.3,55041,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55041,1,3,0)
 ;;=3^Carcinoma in Situ Left Breast,Other Spec Type
